Cancer immunotherapy via nucleic acid aptamers

Khedri, Mostafa; Rafatpanah, Houshang; Abnous, Khalil; Ramezani, Pouria; Ramezani, Mohammad

doi:10.1016/j.intimp.2015.10.013

Cited by 48 publications

(25 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several of the RNA aptamers targeting immune costimulatory receptors (CD28, CD40, OX40 and 4-1BB) have been engineered into multimeric versions to act as receptor agonists for improved cancer immunotherapy 124 . The efficient costimulation on the surface of antigen-presenting cells or T-cells induced by the interaction of a costimulatory receptor and its ligand plays a crucial role in improving anti-tumor immunity 125 .…”

Section: Recent Progress In Aptamer-based Therapeuticsmentioning

confidence: 99%

Aptamers as targeted therapeutics: current potential and challenges

Zhou

Rossi

2016

Nat Rev Drug Discov

1,601

1,316

View full text Add to dashboard Cite

Nucleic acid aptamers, often termed “chemical antibodies”, are functionally comparable to traditional antibodies, but offer several advantages including their relatively small physical size, flexible structure, quick chemical production, versatile chemical modification, high stability, and lack of immunogenicity. In addition, many aptamers internalize upon binding to cellular receptors making them useful targeted delivery agents for siRNAs, microRNAs and conventional drugs. However,Ge several crucial factors, such as their inherent physicochemical characteristics and lack of safety data, have delayed the clinical translation of therapeutic aptamers. This review discusses these challenges, highlighting recent clinical developments and technological advances that have revived impetus for this promising class of therapeutics.

show abstract

Section: Recent Progress In Aptamer-based Therapeuticsmentioning

confidence: 99%

Aptamers as targeted therapeutics: current potential and challenges

Zhou

Rossi

2016

Nat Rev Drug Discov

1,601

1,316

View full text Add to dashboard Cite

show abstract

“…Nucleic acid aptamers can serve as antagonist or agonist and have therefore a direct therapeutic effect by themselves by activating or blocking key cellular functions upon interaction with their cellular targets. Particularly, aptamers have been successfully used as agonists of co-stimulatory receptors, like CD28, OX40 and 4-1BB, in aptamer-mediated cancer immunotherapy [177,178,179]. Multivalent aptamers which induce receptor multimerization, are often more efficient than monovalent aptamers to trigger downstream signaling [87].…”

Section: Applications Of Aptamers In Oncologymentioning

confidence: 99%

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

Mercier

Dontenwill

Choulier

2017

Cancers

View full text Add to dashboard Cite

Aptamers are nucleic acids referred to as chemical antibodies as they bind to their specific targets with high affinity and selectivity. They are selected via an iterative process known as ‘selective evolution of ligands by exponential enrichment’ (SELEX). Aptamers have been developed against numerous cancer targets and among them, many tumor cell-membrane protein biomarkers. The identification of aptamers targeting cell-surface proteins has mainly been performed by two different strategies: protein- and cell-based SELEX, when the targets used for selection were proteins and cells, respectively. This review aims to update the literature on aptamers targeting tumor cell surface protein biomarkers, highlighting potentials, pitfalls of protein- and cell-based selection processes and applications of such selected molecules. Aptamers as promising agents for diagnosis and therapeutic approaches in oncology are documented, as well as aptamers in clinical development.

show abstract

“…However, administration of immune checkpoint blockade with antibodies is associated with immune-related adverse toxicity and resistance [6] in patients. Immune-checkpoint blockades aptamer against PD-1 [7], T-cell immunoglobulin and mucin-domain containing-3 (TIM3) [8], and other immunotherapeutic aptamers [9] offer desired specificity and low immunogenicity as an emerging immunotherapeutic platform.…”

Section: Functionalized Aptamers For Precision Medicinementioning

confidence: 99%